Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy
- 3 March 2017
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 21 (5) , 755-763
Abstract
Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which occurs frequently in the early stages of pediatric-onset cases. Since SLE is a chronic disease associated with frequent disease flares and effective and safe maintenance therapy is required for achieving a favorable outcome, optimal treatment for LN in pubertal patients is a great challenge that remains to be overcome. Although its etiology remains unclear, it has been reported that the innate and adaptive immune systems have been reported to play an important role in the pathogenesis of SLE. However, studies of drugs that have been useful in controlling inflammatory pathways mediated by the innate and adaptive immune systems are now underway. In clinical practice, recent advances in the management of LN, together with earlier renal biopsy and selective use of aggressive immunosuppressive therapy, have contributed to a favorable outcome in children and adolescents with LN. However, the balance of the efficacy of treatment in terms of long-term prognosis and its adverse effects should be weighed in determining the treatment strategy.Keywords
Funding Information
- Grants-in-Aid for Japan Society for Promotion of Science (Grant Numbers 22591175 and 25461615)
This publication has 48 references indexed in Scilit:
- Inflammatory Chemokine Expression via Toll-Like Receptor 3 Signaling in Normal Human Mesangial CellsJournal of Immunology Research, 2013
- Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritisInternational Urology and Nephrology, 2012
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals of the Rheumatic Diseases, 2012
- Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune diseaseClinical and Experimental Nephrology, 2011
- Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and ImidazoquinolinesThe Journal of Immunology, 2011
- Novel Anticytomegalovirus Activity of Immunosuppressant Mizoribine and Its Synergism with GanciclovirThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritisClinical Rheumatology, 2010
- Successful Treatment of Class V+IV Lupus Nephritis with Multitarget TherapyJournal of the American Society of Nephrology, 2008
- Rituximab therapy for juvenile-onset systemic lupus erythematosusPediatric Nephrology, 2007
- Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patientsClinical Rheumatology, 2007